Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer

Published:2022-09 Issue:7 Volume:13 Page:1011-1016
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Hayashi-Tanner Yacki,Polewski Peter J.,Gaddam Mamatha,Fisher Nancy R.,Kovacs Attila J.,Marinier David E.

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference34 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010;363:1290];Hodi;N Engl J Med,2010

2. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge;Alexander;P T,2016

3. An aging world: 2015;He,2016

4. Under-representation of older adults in cancer registration trials: known problem, little progress;Scher;J Clin Oncol,2012

5. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology;Mohile;J Clin Oncol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

2. ICU admission for solid cancer patients treated with immune checkpoint inhibitors;Annals of Intensive Care;2023-04-18